Targeted therapy for advanced lung cancer with EGFR or HER2 changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that has grown after at least one prior treatment.
- A tumor sample shows an EGFR or HER2 gene change.
- You are well enough to be up and about (ECOG 0 or 1).
- You have at least one tumor that can be measured on a scan.
- Your heart, kidney, liver, and blood counts are within acceptable limits.
- You cannot have untreated or worsening brain metastases (some stable brain metastases are allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new EGFR Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.